PL363313A1 - Deuterowane 3-piperydynopropiofenony oraz środki lecznicze zawierające te związki - Google Patents
Deuterowane 3-piperydynopropiofenony oraz środki lecznicze zawierające te związkiInfo
- Publication number
- PL363313A1 PL363313A1 PL02363313A PL36331302A PL363313A1 PL 363313 A1 PL363313 A1 PL 363313A1 PL 02363313 A PL02363313 A PL 02363313A PL 36331302 A PL36331302 A PL 36331302A PL 363313 A1 PL363313 A1 PL 363313A1
- Authority
- PL
- Poland
- Prior art keywords
- deuterated
- piperidinopropiophenones
- illnesses
- muscular
- treatment
- Prior art date
Links
- BIBARRYXKABQKJ-UHFFFAOYSA-N 1-phenyl-3-piperidin-1-ylpropan-1-one Chemical class C=1C=CC=CC=1C(=O)CCN1CCCCC1 BIBARRYXKABQKJ-UHFFFAOYSA-N 0.000 title abstract 4
- 150000001875 compounds Chemical class 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- 230000003387 muscular Effects 0.000 abstract 3
- 150000003839 salts Chemical class 0.000 abstract 2
- 239000000654 additive Substances 0.000 abstract 1
- 239000002671 adjuvant Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/10—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/10—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms
- C07D295/104—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms with the ring nitrogen atoms and the doubly bound oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/108—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms with the ring nitrogen atoms and the doubly bound oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10123129A DE10123129A1 (de) | 2001-05-02 | 2001-05-02 | Deuterierte 3-Piperidinopropiophenone sowie diese Verbindungen enthaltende Arzneimittel |
| PCT/DE2002/001607 WO2002088100A2 (de) | 2001-05-02 | 2002-04-29 | Deuterierte 3-piperidinopropiophenone sowie diese verbindungen enthaltende arzneimittel |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL363313A1 true PL363313A1 (pl) | 2004-11-15 |
Family
ID=7684543
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL02363313A PL363313A1 (pl) | 2001-05-02 | 2002-04-29 | Deuterowane 3-piperydynopropiofenony oraz środki lecznicze zawierające te związki |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US7307091B2 (pl) |
| EP (1) | EP1383752B1 (pl) |
| JP (1) | JP4373097B2 (pl) |
| KR (1) | KR100894846B1 (pl) |
| CN (2) | CN101002770A (pl) |
| AT (1) | ATE298324T1 (pl) |
| AU (1) | AU2002257562B2 (pl) |
| CA (1) | CA2446890C (pl) |
| CZ (1) | CZ20033060A3 (pl) |
| DE (2) | DE10123129A1 (pl) |
| DK (1) | DK1383752T3 (pl) |
| ES (1) | ES2244768T3 (pl) |
| HU (1) | HUP0400077A2 (pl) |
| IL (1) | IL158668A0 (pl) |
| IS (1) | IS7006A (pl) |
| NO (1) | NO20034863L (pl) |
| NZ (1) | NZ529586A (pl) |
| PL (1) | PL363313A1 (pl) |
| PT (1) | PT1383752E (pl) |
| RU (1) | RU2296755C2 (pl) |
| SI (1) | SI1383752T1 (pl) |
| WO (1) | WO2002088100A2 (pl) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10261807A1 (de) * | 2002-12-19 | 2004-07-01 | Turicum Drug Development Ag | Deuterierte Catecholaminderivate sowie diese Verbindungen enthaltende Arzneimittel |
| HUP0300929A3 (en) * | 2003-04-09 | 2005-06-28 | Richter Gedeon Vegyeszet | Analgetic and/or muscle relaxant pharmaceutical composition |
| DE102005014080B4 (de) * | 2005-03-21 | 2007-11-22 | Birds Pharma Gmbh Berolina Innovative Research & Development Services | Additionssalze des Tolperison, Verfahren zu deren Herstellung, Verwendung derselben und diese enthaltende Arzneimittel |
| US7601737B2 (en) * | 2005-07-26 | 2009-10-13 | Nycomed Gmbh | Isotopically substituted proton pump inhibitors |
| BRPI0614039A2 (pt) * | 2005-07-26 | 2011-03-09 | Nycomed Gmbh | inibidores isotopicamente substituìdos da bomba de prótons |
| WO2007012651A1 (en) * | 2005-07-26 | 2007-02-01 | Nycomed Gmbh | Isotopically substituted pantoprazole |
| CA2624179A1 (en) * | 2005-10-06 | 2007-04-12 | Auspex Pharmaceuticals, Inc. | Deuterated inhibitors of gastric h+, k+-atpase with enhanced therapeutic properties |
| US8604031B2 (en) | 2006-05-18 | 2013-12-10 | Mannkind Corporation | Intracellular kinase inhibitors |
| AU2007286186A1 (en) * | 2006-08-08 | 2008-02-21 | Auspex Pharmaceuticals, Inc. | Preparation and utility of substituted quinazoline compounds with alpha-adrenergic blocking effects |
| EP2611759A1 (en) * | 2010-09-03 | 2013-07-10 | Ivax International Gmbh | Deuterated analogs of pridopidine useful as dopaminergic stabilizers |
| IL321987A (en) | 2013-12-03 | 2025-09-01 | Intra Cellular Therapies Inc | A long-acting injectable preparation containing polymeric microspheres of modified compressed gamma-carboline heterocyclic compounds or a sustained-release pharmaceutical preparation containing these compounds for use in the treatment of bipolar I and/or bipolar II disorders |
| WO2015154025A1 (en) * | 2014-04-04 | 2015-10-08 | Intra-Cellular Therapies, Inc. | Organic compounds |
| WO2017105881A1 (en) * | 2015-12-15 | 2017-06-22 | NeuForm Pharmaceuticals, Inc. | Deuterated compounds for treating pain |
| EP3407889B1 (en) | 2016-03-25 | 2021-05-19 | Intra-Cellular Therapies, Inc. | Organic compounds and their use in treating or preventing central nervous system disorders |
| US11331316B2 (en) | 2016-10-12 | 2022-05-17 | Intra-Cellular Therapies, Inc. | Amorphous solid dispersions |
| CN106588817A (zh) * | 2016-12-13 | 2017-04-26 | 湖南亚大制药有限公司 | 一种盐酸乙哌立松的合成方法 |
| WO2018175969A1 (en) | 2017-03-24 | 2018-09-27 | Intra-Cellular Therapies, Inc. | Novel compositions and methods |
| WO2020047241A1 (en) | 2018-08-29 | 2020-03-05 | Intra-Cellular Therapies, Inc. | Novel compositions and methods |
| KR20210052472A (ko) | 2018-08-31 | 2021-05-10 | 인트라-셀룰라 써래피스, 인코퍼레이티드. | 신규한 방법 |
| WO2020047407A1 (en) | 2018-08-31 | 2020-03-05 | Intra-Cellular Therapies, Inc. | Novel methods |
| BR112022000231A2 (pt) | 2019-07-07 | 2022-02-22 | Intra Cellular Therapies Inc | Novos métodos |
| CN110845443B (zh) * | 2019-12-11 | 2023-09-05 | 嘉实（湖南）医药科技有限公司 | 一种制备高纯度盐酸托哌酮的方法 |
| US12414948B2 (en) | 2022-05-18 | 2025-09-16 | Intra-Cellular Therapies, Inc. | Methods |
| CN117003605B (zh) * | 2023-08-07 | 2024-06-11 | 宁波萃英化学技术有限公司 | 一种氘代萘基蒽类化合物的制备方法 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5527914B2 (pl) * | 1973-12-14 | 1980-07-24 | ||
| US3995047A (en) * | 1973-12-14 | 1976-11-30 | Eisai Co., Ltd. | Propiophenone derivatives in the treatment of pathological muscular conditions |
| US4567264A (en) * | 1983-05-18 | 1986-01-28 | Syntex (U.S.A.) Inc. | Cardioselective aryloxy- and arylthio- hydroxypropylene-piperazinyl acetanilides which affect calcium entry |
| HU33131A (pl) * | 1984-01-26 | 1984-10-29 |
-
2001
- 2001-05-02 DE DE10123129A patent/DE10123129A1/de not_active Withdrawn
-
2002
- 2002-04-29 RU RU2003133924/04A patent/RU2296755C2/ru not_active IP Right Cessation
- 2002-04-29 PT PT02727303T patent/PT1383752E/pt unknown
- 2002-04-29 AU AU2002257562A patent/AU2002257562B2/en not_active Ceased
- 2002-04-29 NZ NZ529586A patent/NZ529586A/en unknown
- 2002-04-29 US US10/476,743 patent/US7307091B2/en not_active Expired - Lifetime
- 2002-04-29 DK DK02727303T patent/DK1383752T3/da active
- 2002-04-29 EP EP02727303A patent/EP1383752B1/de not_active Expired - Lifetime
- 2002-04-29 HU HU0400077A patent/HUP0400077A2/hu unknown
- 2002-04-29 ES ES02727303T patent/ES2244768T3/es not_active Expired - Lifetime
- 2002-04-29 PL PL02363313A patent/PL363313A1/pl unknown
- 2002-04-29 AT AT02727303T patent/ATE298324T1/de not_active IP Right Cessation
- 2002-04-29 DE DE50203456T patent/DE50203456D1/de not_active Expired - Lifetime
- 2002-04-29 CN CNA2006101485698A patent/CN101002770A/zh active Pending
- 2002-04-29 CN CNB028106121A patent/CN1293064C/zh not_active Expired - Fee Related
- 2002-04-29 CA CA2446890A patent/CA2446890C/en not_active Expired - Fee Related
- 2002-04-29 CZ CZ20033060A patent/CZ20033060A3/cs unknown
- 2002-04-29 IL IL15866802A patent/IL158668A0/xx unknown
- 2002-04-29 WO PCT/DE2002/001607 patent/WO2002088100A2/de not_active Ceased
- 2002-04-29 JP JP2002585402A patent/JP4373097B2/ja not_active Expired - Fee Related
- 2002-04-29 SI SI200230177T patent/SI1383752T1/sl unknown
- 2002-04-29 KR KR1020037014301A patent/KR100894846B1/ko not_active Expired - Fee Related
-
2003
- 2003-10-30 IS IS7006A patent/IS7006A/is unknown
- 2003-10-31 NO NO20034863A patent/NO20034863L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| DE10123129A1 (de) | 2002-11-14 |
| JP4373097B2 (ja) | 2009-11-25 |
| IL158668A0 (en) | 2004-05-12 |
| KR20040015240A (ko) | 2004-02-18 |
| HUP0400077A2 (hu) | 2004-04-28 |
| CZ20033060A3 (cs) | 2004-09-15 |
| CA2446890A1 (en) | 2002-11-07 |
| ATE298324T1 (de) | 2005-07-15 |
| US20040186136A1 (en) | 2004-09-23 |
| KR100894846B1 (ko) | 2009-04-24 |
| RU2296755C2 (ru) | 2007-04-10 |
| WO2002088100A3 (de) | 2003-05-30 |
| EP1383752B1 (de) | 2005-06-22 |
| CN101002770A (zh) | 2007-07-25 |
| NO20034863L (no) | 2003-12-30 |
| PT1383752E (pt) | 2005-11-30 |
| AU2002257562B2 (en) | 2007-01-11 |
| CN1527823A (zh) | 2004-09-08 |
| DE50203456D1 (de) | 2005-07-28 |
| CA2446890C (en) | 2010-02-23 |
| RU2003133924A (ru) | 2005-05-10 |
| JP2004527558A (ja) | 2004-09-09 |
| EP1383752A2 (de) | 2004-01-28 |
| US7307091B2 (en) | 2007-12-11 |
| ES2244768T3 (es) | 2005-12-16 |
| IS7006A (is) | 2003-10-30 |
| WO2002088100A2 (de) | 2002-11-07 |
| NZ529586A (en) | 2005-07-29 |
| SI1383752T1 (sl) | 2005-12-31 |
| DK1383752T3 (da) | 2005-10-17 |
| CN1293064C (zh) | 2007-01-03 |
| NO20034863D0 (no) | 2003-10-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL158668A0 (en) | Deuterated 3-piperidinopropiophenone and medicaments containing said compounds | |
| AP1818A (en) | Urea-compounds active as vanilloid receptor antagonists for the treatment of pain | |
| EA200301165A1 (ru) | Лекарственное средство на основе оксикодона | |
| WO2005065069A3 (en) | Pharmaceutical methods, dosing regimes and dosage forms for the treatment of alzheimer's disease | |
| WO2004112711A3 (en) | Oral extended-release composition | |
| GEP20074208B (en) | Substituted amides active at the cannabinoid-1 receptor | |
| IL149147A0 (en) | Use of oxcarbazepine for the manufacture of oral dosage form medicament | |
| BG66093B1 (bg) | Състави с контролирано освобождаване, съдържащи нимесулид | |
| UA90858C2 (ru) | Композиция с контролируемым высвобождением варденафила | |
| MX2007015480A (es) | Formulaciones de dosificacion solida de medicamentos narcoticos que tienen adsorcion bucal mejorada. | |
| SE9901573D0 (sv) | New compounds | |
| AP2003002763A0 (en) | Controlled release formulations for oral administration | |
| SE0102440D0 (sv) | New compound | |
| CA2389032A1 (en) | Preventive or therapeutic agents for inflammatory diseases of intestine | |
| GR1004358B (el) | Ανυδρη κρυσταλλικη μορφη της βαλακyκλοβιρης υδροχλωρικης | |
| WO2006072940A3 (en) | Controlled long acting release pharmaceutical preparation for use in the oral cavity | |
| NO20063277L (no) | Farmasoytisk sammensetning av vinflunin som er ment for parenteral administrering, fremstillingsmate og anvendelse derav | |
| MY137570A (en) | Method for the preparation of a pharmaceutical composition comprising 5-aminosalicyclic acid for use in treatment of ulcerative colitis crohn's disease | |
| PL368686A1 (pl) | Nowe aminobenzofenony | |
| CA2385755A1 (en) | Prevention of colorectal cancer | |
| MXPA02011533A (es) | Nuevas formulaciones de alfa-2,4-disulfofenil-n-terc-butilnitrona. | |
| SG145717A1 (en) | Composition for releasing a weak base for an extended period of time | |
| SE9901572D0 (sv) | New compounds | |
| WO2005082413A3 (en) | Ciclesonide and glycopyrronium combination | |
| GEP20043377B (en) | Pharmaceutical Complex |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| DISC | Decisions on discontinuance of the proceedings (taken after the publication of the particulars of the applications) |